Browse Studies About FAQ

Sign in Get started

Match. Apply. Get paid. The simplest way to participate in paid clinical research.

Product

Browse Studies How it Works Verification Arctuva Pro For Sponsors

Company

About Contact FAQ

Legal

Privacy Terms of Service Security Accessibility Transparency Report

© 2026 Arctuva, Inc. All rights reserved.

Compensation is for time and inconvenience, not income.

Browse Studies — Arctuva | Arctuva

Browse studies

Find your next paid study

2 recruiting studies matching your filters

Newest first Highest paying

Filters

Condition

Location

Phase

Min compensation ($)

Max compensation ($)

Study Assessing the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

This study is designed to demonstrate the efficacy and assess safety and tolerability of oral daily alpelisib in participants with PIK3CA-related overgrowth sp…

PIK3CA-related Overgrowth Spectrum (PROS)

~$10 – $8,750

Novartis PharmaceuticalsNCT06997588

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and chi…

PIK3CA-Related Overgrowth Spectrum (PROS)Lymphatic MalformationsVascular Malformations+5 more

~$10 – $8,750

Relay Therapeutics, Inc.NCT06789913